---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-23-001171"
form_type: "8-K"
ticker: null
cik: "0001584751"
company_name: "Talis Biomedical Corp"
filed_at: "2023-01-25T23:59:59+00:00"
generated_at: "2026-06-20T09:30:42.973699+00:00"
event_type: "other_material"
sentiment: "negative"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Talis Biomedical receives 180-day extension to meet Nasdaq $1 bid price rule; deadline July 24, 2023

## Summary
- Transferred stock listing from Nasdaq Global Market to Capital Market on Jan 24, 2023.
- Received additional 180-day grace period, until July 24, 2023, to meet $1.00 minimum bid price.
- Must have closing bid price at least $1.00 for 10 consecutive business days to regain compliance.
- Intends to cure deficiency by effecting a reverse stock split if necessary.

## SEC filing metadata
- accession: 0000950170-23-001171
- form_type: 8-K
- cik: 0001584751
- company_name: Talis Biomedical Corp
- filed_at: 2023-01-25T23:59:59+00:00
- event_type: other_material
- sentiment: negative
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 3.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1584751/000095017023001171/0000950170-23-001171-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1584751/000095017023001171/tlis-20230124.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-23-001171
- JSON: https://secwatch.observer/filing/0000950170-23-001171.json
- Plain text: https://secwatch.observer/filing/0000950170-23-001171.txt

## Key facts
- Listing & Compliance Notices
  Talis Biomedical Corp received a nasdaq deficiency notice notice regarding minimum bid price (rules 5450(a)(1)).
  - Exchange: nasdaq
  - Notice: deficiency notice
  - Deficiency: minimum bid price
  - Rules: 5450(a)(1)
  source text: January 24, 2023, the Company transferred the listing of its securities to the Nasdaq Capital Market (the "Capital Market") and received notice from Nasdaq indicating that, while the Company has not regained compliance with the Bid Price Requirement, Nasdaq has determined that the Company is eligible for an additional 180-day period, or until July 24, 2023, to regain compliance. According to the notification from Nasdaq, the Staff’s determination was based on: (i) the Company meeting the continued listing requirement for market value of publicly held shares and all other applicable requirement
  evidence_url: https://www.sec.gov/Archives/edgar/data/1584751/000095017023001171/0000950170-23-001171-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.